https://www.novumpr.nl/2018/10/01/seattle-genetics-en-takeda-kondigen-positieve-resultaten-aan-van-fase-3-echelon-2-klinische-proef-waarbij-adcetris-brentuximab-vedotin-in-frontline-cd30-expressing-peripheral-t-cell-lymphoma-w/?utm_source=rss&utm_medium=rss&utm_campaign=seattle-genetics-en-takeda-kondigen-positieve-resultaten-aan-van-fase-3-echelon-2-klinische-proef-waarbij-adcetris-brentuximab-vedotin-in-frontline-cd30-expressing-peripheral-t-cell-lymphoma-w NovumPR press releases Mon, 01 Oct 2018 15:07:15 +0000 hourly 1 https://wordpress.org/?v=6.8.2